Institution Directory

Clinical trials at Massachusetts General Hospital

Sites in Boston, MA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1487

Shown on this page

Current sort

Live official records

Conditions: AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis, Generalized Myasthenia Gravis (gMG)
Interventions: Efgartigimod IV, Empasiprubart IV; Biological
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 14
States / cities: Carlsbad, California • Miami, Florida • Tampa, Florida + 11 more

Conditions: NMOSD
Interventions: Rituximab (R), Eculizumab (Soliris®), Ravulizumab, Satralizumab, Inebilizumab; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Spinal Muscular Atrophy Type I, Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type III, SMA
Interventions: Onasemnogene Abeparvovec-xioi; Biological
Lead sponsor: Novartis Gene Therapies; Industry
Eligibility: Not listed
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2035
U.S. locations: 18
States / cities: Palo Alto, California • Aurora, Colorado • Chicago, Illinois + 14 more

Conditions: Breast Cancer
Interventions: Paclitaxel, Trastuzumab, Pertuzumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 5
States / cities: Boston, Massachusetts • Milford, Massachusetts • South Weymouth, Massachusetts

Conditions: Metastatic Castration Resistant Prostate Cancer, mCRPC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, mCRPC or Advanced/Metastatic Solid Tumors, mCRPC, Metastatic Castration Resistant Prostate Cancer, Neoplasms Prostate, Neoplasms of Prostate
Interventions: FX-111; Drug
Lead sponsor: Flare Therapeutics Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 10
States / cities: Los Angeles, California • Boston, Massachusetts • Grand Rapids, Michigan + 6 more

Conditions: Septic Shock
Interventions: Angiotensin II, Norepinephrine; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts • Winston-Salem, North Carolina

Conditions: Coronary Artery Disease
Interventions: PCI with SELUTION SLR DCB, PCI with FDA approved "-limus" DES; Device
Lead sponsor: M.A. Med Alliance S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 65
States / cities: Jonesboro, Arkansas • Chula Vista, California • Los Angeles, California + 54 more

Conditions: Breast Neoplasms, Carcinoma, Ductal, Breast, Receptors, Estrogen (for ER-positive Requirement)
Interventions: ctDNA-Guided Treatment Strategy; Device
Lead sponsor: Natera, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 725 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2037
U.S. locations: 49
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 44 more

Conditions: Sensation Disorders, Sensation, Phantom, Pain, Postoperative, Pain, Chronic, Numbness, Sensory Disorder, Sensory Defect, Phantom Pain, Phantom Sensation
Interventions: Sensory testing; Diagnostic Test
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2033
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Resected Pancreatic Adenocarcinoma
Interventions: daraxonrasib; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 43
States / cities: Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 33 more

Conditions: Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Cholangiocarcinoma
Interventions: Afatinib, Pemigatinib; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Pre-exposure Prophylaxis Use
Interventions: Choice of follow up, Follow up via standard clinic; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

About this Massachusetts General Hospital institution page

What this page lists: ClinicalTrials.gov records that list Massachusetts General Hospital in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Massachusetts General Hospital

Filter and sort this campus

Live official records

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD

Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi

DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC

A Study in Patients With Metastatic Castration-Resistant Prostate Cancer

Mechanistic Assessment of Norepinephrine Therapy vs. Angiotensin-II in Septic Shock

SELUTION 4 De Novo Small Vessel IDE Trial

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Prospective Study of Sensation and Satisfaction in Cancer and Transgender Mastectomy Patients

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

PrEP4U: Assessing the Effectiveness of Integrated Same-Day Lenacapavir Initiation and Follow-up Choice on PrEP Persistence

About this Massachusetts General Hospital institution page